Listen in to global fucoidan news
Marinova is pleased to have published its first audiobook, ‘Fucoidans: A world of clinical possibilities.’ Read more
Latest news
The effect of fucoidan on prostate cancer
Marinova is pleased to announce a comprehensive research program investigating the effect of fucoidan on prostate cancer. Read more
Special edition newsletter: Immune health
Marinova is pleased to present a special edition newsletter focused on immune health. Read more
Immune health market report
A new report published by Vitafoods Insights provides a comprehensive review of the state of the immune health market. Read more
Update 2: Fucoidan and novel coronavirus (COVID-19)
An update on Maritech® fucoidan and COVID-19. Read more
Fucoidan reduces flu severity
Australian researchers have demonstrated that a natural compound derived from seaweed is effective in significantly reducing clinical symptoms and lung damage in a severe Influenza A H1N1 model. Read more
TGA advertising reforms
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. Recent therapeutic goods advertising reforms implemented by the TGA include a stronger compliance framework, an amended Therapeutic Goods Advertising Code, and a single body for compliance and complaints handling. Read more
Nutritional Outlook showcases marine ingredients
Nutritional Outlook magazine has drawn attention to the flourishing marine ingredients market in their April 2020 edition. Read more
Fucoidan nanotechnology advancing cancer research
A recently conducted study involving Marinova's Undaria pinnatifida fucoidan is contributing to cancer research. Read more
Fucoidan as a surface coating for biomaterials
Fucoidan is a promising candidate for the development of new materials in the medical device sector. Read more